Predictive Diagnostics: Market Research Report

January 2019 | 186 pages | ID: P23338F5AB6EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Predictive Diagnostics in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 47 companies including many key and niche players such as -

• Abbott Molecular
• Almac Group Ltd.
• Ambry Genetics Corporation
• BioGenex
• Epistem Ltd.
• F. Hoffmann-La Roche Ltd.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

A Curtain Raiser
Predictive Diagnostics – A Key Segment of Genetic Testing
Outlook for Predictive Diagnostics Market
Prospects for Predictive Genetic Diagnostics Grow Brighter
Oncology: A Key Growth Driver for Predictive Diagnostics
Genes and Associated Cancers/Tumors
Predictive Diagnostics - Crucial for Breast Cancer Management

Table 1. Worldwide Breast Cancer Incidence and Mortality Rates by Region: 2018 (includes corresponding Graph/Chart)

Table 2. Worldwide Breast Cancer Incidence Rates in Female Population by Region: 2018 (includes corresponding Graph/Chart)

Inherited Breast Cancer – An Important End-use Market for Predictive Diagnostics
About BRCA1 and BRCA2
Breast Cancer Gene Testing Market to Expand Strongly
Myriad Genetics-The Unquestioned Leader in Breast Cancer Testing
The First FDA-Approved DTC Breast Cancer Genetic Assay
Limitations of Breast Cancer Screening
Growing Popularity of Multi-gene Panels in Clinical Cancer Genetics

Table 3. Cancer Panels from Select Leading Players

Clinical Characteristics of Moderate-High Penetrance Genes Other than BRCA1/2
Challenges Associated with Multigene-Panel Testing
Next-Generation Sequencing – A Giant Leap in Genome Sequencing
Genes Included in NGS Panels
Increasing Incidence of Colorectal Cancer in <50 Age Group: A Business Case for Predictive Diagnostics

Table 4. Worldwide Colorectal Cancer Incidence and Mortality Rates by Region: 2018 (includes corresponding Graph/Chart)

Table 5. Worldwide Colorectal Cancer Incidence Rates in Male and Female Population: 2018 (includes corresponding Graph/Chart)

Growing Number of Colorectal Cancer Risk Population with Lynch Syndrome
Genes Associated with Inherited Risk of Colorectal Cancer
Launch of PromarkerD: Hope for Early Diagnosis of Diabetic Kidney Disease
What is PromarkerD?
Patents for PromarkerD

3. SELECT PREDICTIVE DIAGNOSTIC TESTS/ASSAYS AVAILABLE

The BRACAnalysis Assay
Oncotype Dx Prostate Cancer Assay
Myrisk Hereditary Cancer Panel
EndoPredict
LifeKit Predict
Prolaris Genetic Test
SelectMDx
Breast Cancer Index (BCI) Test
The PancraGEN Assay
Proove Opioid Response Assay
VeriStrat Test
BRAF Mutation Detection Assay
Oncotype Dx Colon Cancer Test
ColoPrint 18-Gene Colon Cancer Recurrence Test
ROMA Assay
Panexia Assay
CytoScan Dx Assay
Oncotype Dx Breast Cancer Assay

4. GROWTH DRIVERS, MARKET TRENDS AND ISSUES

Rising Incidence and Prevalence of CDDs: A Major Growth Driver
Increasing Cancer Disease Burden Drives the Demand for Predictive Diagnostics

Table 6. Total Number of Cancer Deaths: 2018 (includes corresponding Graph/Chart)

Table 7. Global Cancer Incidence by Type: 2018 (includes corresponding Graph/Chart)

Incidence of Neurodegenerative Diseases Increasing
Alzheimer’s Disease
Huntington’s Disease
Quick Facts on the Global Prevalence of Huntington's Disease
Parkinson’s Disease
Ballooning Global Population Offers Significant Growth Opportunities

Table 8. Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)

Table 9. Global Population Statistics for the 65+ Age Group by Select Countries: 2016 (includes corresponding Graph/Chart)

Predictive Diagnostics Enable Higher Life Expectancy

Table 10. Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)

Table 11. Global Population Statistics for the 60+ Age Group by Region: 2017 (includes corresponding Graph/Chart)

Widening of Insurance Coverage for Hereditary Cancer Testing
Discovery of Novel Biomarkers - Crucial to Predictive Diagnostics
Genomic Research Remains Confined to Fundamental Research
Unresolved Issues Hamper Widespread Implementation of Genetic Testing for Monogenetic Disease
Dearth of Genetic Counselors – A Major Hurdle for the Predictive Genetic Testing
Framework for Validation, Regulation, and Ethical Issues – The Need of the Hour

5. PRODUCT OVERVIEW

Introduction
Underlying Principles of Predictive Diagnostics
Predictive Diagnostics Vis-a-vis Conventional Testing
Characteristics of an Effective Predictive Diagnostic Test
Applications of Predictive Diagnostics
Pre-Symptomatic
Predisposition Testing
Cancer Testing
Carrier Identification
Steps in Genetic Testing Process
Limitations
Risks and Other Limitations of Genetic Testing
Select Diseases Identified Using Predictive Diagnostics
Cystic Fibrosis
Breast and Ovarian Cancer (BRCA)
Alzheimer's Disease
Colorectal Cancer
Hemochromatosis (HH)
Huntington's Disease (HD)
Costs of Select Tests

Table 12. Costs of Select Genetic Tests

Medical Ethics Surrounding Predictive Diagnostics

6. COMPETITIVE LANDSCAPE

6.1 Focus on Select Key Players
Abbott Molecular (USA)
Almac Group Ltd. (Ireland)
Ambry Genetics Corporation (USA)
BioGenex (USA)
Epistem Ltd. (UK)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genomic Health, Inc. (USA)
MDxHEALTH, Inc. (USA)
Myriad Genetics, Inc. (USA)
OPKO Health, Inc. (USA)
Prometheus Laboratories Inc. (USA)
Proteomics International Laboratories Ltd (Australia)
QIAGEN N. V. (The Netherlands)
6.2 Product Introductions
BaseHealth Introduces First Predictive Analytics Platform
Predictive Diagnostics Introduces Endometriosis Risk Test
Proteomics International Enters into Licensing Agreement with PrismHealthDx for the Launch of PromarkerD Predictive Test in the US
SQI Diagnostics and Predictive Health Diagnostics Introduces Revolutionary Predictive Cardiac Test
QIAGEN Introduces Predictive Therascreen PITX2 Test in Europe
Proteomics International Laboratories Announces the Official Launch of Predictive diagnostic test, PromarkerD
MDxHealth Introduces AssureMDx for Bladder Cancer Liquid Biopsy Test
LabCorp Introduces Sera Prognostics’ PreTRM Test
Proteomics International Laboratories presents an update on commercialisation progress for the PromarkerD test
6.3 Recent Industry Activity
FDA Authorizes First Direct-to-Consumer Genetic Test from 23andMe for Cancer Risk
Proteomics International Agrees with PrismHealthDx for Launching PromarkerD predictive test in the US
Proteomics International Announces the Availability of PromarkerD kit version for Imminent Commercial Release
Proteomics International Collaborates with Janssen to Evaluate PromarkerD Kidney Disease Test
Predictive Technology Group Completes the Acquisition of Inception Dx
Epistem Announces the Completion of Management Buyout
MDxHealth Enters into Worldwide Licencing Agreement with Philips for Prognostic Prostate Cancer Biomarker
Konica Minolta Completes the Acquisition of U. S. -based Ambry Genetics
Color Genomics Receives Investments from High-Profile Investors
SQI Diagnostics Sells Automated Sqidlite Platform to Predictive Cardiac Customer
MDxHealth Associates with Ferrer to Distribute SelectMDx in Spain
Prescient Medicine Acquires PGxL Laboratories

7. GLOBAL MARKET PERSPECTIVE

Table 13. World Recent Past, Current & Future Analysis for Predictive Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 14. World Historic Review for Predictive Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 15. World 14-Year Perspective for Predictive Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for the Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

8. REGIONAL MARKET PERSPECTIVE

8.1 The United States
A. Market Analysis
Market Outlook
Genetic Information Nondiscrimination Act (GINA) Boosts Genetic Testing
High Frequency of Predictive CFTR Screening in Expectant Mothers
Rising Cancer Disease Burden – An Opportunity Indicator

Table 16. New Cancer Cases in the US by State (2017E) (includes corresponding Graph/Chart)

Table 17. Number of Deaths Related to Major Types of Cancer in US by State: 2017E (includes corresponding Graph/Chart)

Table 18. New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)

Table 19. Cancer Related Deaths by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)

B. Market Analytics

Table 20. The US Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 21. The US Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

8.2 Canada
A. Market Analysis

Table 22. Cancer Incidence in Canada by Gender and Affected Site: 2017 (includes corresponding Graph/Chart)

Table 23. Cancer Incidence in Canada by Province: 2017E (includes corresponding Graph/Chart)

Table 24. Cancer Incidence in Canada by Age Group: 2017E (includes corresponding Graph/Chart)

Table 25. Cancer Related Deaths in Canada by Gender and Affected Site: 2017E (includes corresponding Graph/Chart)

B. Market Analytics

Table 26. Canadian Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 27. Canadian Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

8.3 Japan
A. Market Analysis

Table 28. Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)

Table 29. Japanese Population by Age Group (2017E): Percentage Breakdown for 0-14 Years, 15-24 Years, 25-54 Years, 55-64 Years, 65 Years and Above (includes corresponding Graph/Chart)

B. Market Analytics

Table 30. Japanese Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 31. Japanese Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

8.4 Europe
A. Market Analysis
Predictive Testing to Dominate Genetic Testing and Screening Services in Europe
Increasing Testing Needs of the Elderly: Business Case for Predictive Diagnostics

Table 32. EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart)

Cancer Statistics in Europe

Table 33. Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart)

B. Market Analytics

Table 34. European Recent Past, Current & Future Analysis for Predictive Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 35. European Historic Review for Predictive Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 36. European 14-Year Perspective for Predictive Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, and Rest of Europe Markets for the Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

  8.4.1 France
Market Analysis

Table 37. French Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 38. French Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

  8.4.2 Germany
Market Analysis

Table 39. German Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 40. German Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

  8.4.3 Italy
Market Analysis

Table 41. Italian Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 42. Italian Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

  8.4.4 The United Kingdom
A. Market Analysis
Current and Future Analysis
UK Government Encourages Genetic Testing
B. Market Analytics

Table 43. The UK Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 44. The UK Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

  8.4.5 Rest of Europe
Market Analysis

Table 45. Rest of European Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 46. Rest of European Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

8.5 Asia-Pacific
A. Market Analysis

Table 47. Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)

B. Market Analytics

Table 48. Asia-Pacific Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 49. Asia-Pacific Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

8.6 Rest of World
Market Analysis

Table 50. Rest of World Recent Past, Current & Future Analysis for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 51. Rest of World Historic Review for Predictive Diagnostics Market Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)

9. COMPANY PROFILES

Total Companies Profiled: 47 (including Divisions/Subsidiaries - 48)
The United States (27)
Canada (1)
Europe (15)
  Germany (4)
  The United Kingdom (6)
  Spain (1)
  Rest of Europe (4)
Asia-Pacific (Excluding Japan) (4)
Middle East (1)